Core Viewpoint - Wandercraft has successfully completed a $75 million Series D financing round, bringing its total funding to approximately $137 million, which will be used to commercialize its products and expand its operations in the rehabilitation and industrial robotics sectors [1][3][14]. Financing Purpose and Development Plan - The financing will primarily support the commercialization of the Eve system, international deployment of Atalante X, validation of Calvin-40 for mass production, team expansion, and algorithm optimization [3][14]. - The company plans to increase its workforce from 100 to 150 employees to enhance R&D, production, and sales capabilities [3]. Product Overview - **Atalante X**: A self-balancing exoskeleton system designed for rehabilitation institutions, targeting patients with mobility impairments due to spinal cord injuries, strokes, multiple sclerosis, and Parkinson's disease. It has received CE certification and FDA approval for various rehabilitation uses and has been deployed in over 100 rehabilitation centers globally, serving more than 2,500 patients [7][8]. - **Eve**: A portable exoskeleton system aimed at individual users for daily standing and walking support in home and community settings. Currently in clinical trials, it is expected to launch in the U.S. market in 2026 [10][11]. - **Calvin-40**: The first humanoid robot developed for industrial applications, designed to assist in repetitive or high-risk physical labor tasks. It is set to be deployed in Renault's factories by the end of 2025 [13][14]. Strategic Partnerships and Market Position - Renault Group is not only an investor but also a key partner providing manufacturing support for Calvin-40, which will be its first commercial user [4][14]. - Wandercraft's clear product evolution, reasonable pipeline structure, and strong partnerships contribute to its attractiveness to investors, especially in a tightening macro financing environment [14][15]. Company Background - Founded in 2012, Wandercraft has over 100 employees and holds more than 30 patents in dynamic balance control and gait neural network modeling. The company is transitioning from a single rehabilitation system manufacturer to a multi-scenario robotics platform enterprise [14][15].